Consolidated Financial Statements
Years Ended December 31, 2018 and 2017



#### **Report of Independent Registered Public Accounting Firm**

To the Board of Directors and Shareholders of Village Farms International, Inc.

#### Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial position of Village Farms International, Inc. and its subsidiaries (together, the Company) as of December 31, 2018 and 2017, and the related consolidated statements of changes in shareholders' equity, (loss) income and comprehensive income, and cash flows for the years then ended, including the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and their financial performance and their cash flows for the years then ended in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).

#### **Basis for Opinion**

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.



Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

## (Signed) "PricewaterhouseCoopers LLP"

**Chartered Professional Accountants** 

Vancouver, Canada March 13, 2019

We have served as the Company's auditor since 2006.

# Village Farms International, Inc. Consolidated Statements of Financial Position (In thousands of United States dollars)

|   | Decem | December 31, 2017 |    |         |
|---|-------|-------------------|----|---------|
| ASSETS  |       |                   |    |         |
| Current assets                                  |       |                   |    |         |
| Cash and cash equivalents                       | \$    | 11,920            | \$ | 7,091   |
| Trade receivables                               |       | 11,292            |    | 11,259  |
| Amounts due from joint venture                  |       | 10,873            |    | 411     |
| Other receivables                               |       | 332               |    | 1,571   |
| Inventories (note 5)                            |       | 22,485            |    | 17,309  |
| Prepaid expenses and deposits                   |       | 889               |    | 810     |
| Biological asset (note 6)                       |       | 4,230             |    | 4,405   |
| Total current assets                            |       | 62,021            | -  | 42,856  |
| Non-current assets                              |       |                   |    |         |
| Property, plant and equipment (note 7)          |       | 77,479            |    | 81,754  |
| Investment in joint venture (note 8)            |       | 18,108            |    | 15,727  |
| Other assets (note 9)                           |       | 2,207             |    | 2,004   |
| Total assets                                    | \$    | 159,815           | \$ | 142,341 |
| LIABILITIES                                     |       |                   |    |         |
| Current liabilities                             |       |                   |    |         |
| Line of credit                                  |       | 2,000             |    | -       |
| Trade payables                                  | \$    | 14,601            | \$ | 12,952  |
| Current maturities of long-term debt (note 10)  |       | 3,414             |    | 2,620   |
| Accrued liabilities                             |       | 3,509             |    | 3,793   |
| Current maturities of capital lease obligations |       | 78                |    | 72      |
| Total current liabilities                       |       | 23,602            |    | 19,437  |
| Non-current liabilities                         |       |                   |    |         |
| Long-term debt (note 10)                        |       | 32,445            |    | 35,760  |
| Deferred tax liability (note 16)                |       | 1,920             |    | 4,825   |
| Other liabilities                               |       | 1,050             |    | 1,097   |
| Capital lease obligations                       |       | 102               |    | 179     |
| Total liabilities                               |       | 59,119            |    | 61,298  |
| SHAREHOLDERS' EQUITY                            |       |                   |    |         |
| Share capital (note 20)                         |       | 60,872            |    | 36,115  |
| Contributed surplus                             |       | 2,198             |    | 1,726   |
| Revaluation surplus (note 7)                    |       | 4,321             |    | 4,321   |
| Accumulated other comprehensive loss            |       | (562)             |    | (391)   |
| Retained earnings                               |       | 33,867            |    | 39,272  |
| Total shareholders' equity                      |       | 100,696           |    | 81,043  |
| Total liabilities and shareholders' equity      | \$    | 159,815           | \$ | 142,341 |

Subsequent event (note 24)

## $Consolidated \, Statements \,\, of \,\, Changes \,\, in \,\, Shareholders' \,\, Equity$

#### For the Years Ended December 31, 2018 and 2017

 $(In\ thousands\ of\ United\ States\ dollars, except\ for\ shares\ outstanding)$ 

|  | Number of<br>Common<br>Shares | Share<br>Capital |        | Contributed<br>Surplus |       | Revaluation<br>Surplus |         | Accumulated Other Comprehensive (Loss) Income |       | Retained<br>Earnings |         | Total<br>Shareholders'<br>Equity |         |
|--|-------------------------------|------------------|--------|------------------------|-------|------------------------|---------|---|-------|----------------------|---------|----------------------------------|---------|
| Balance at January 1, 2017   | 38,882,945                    | \$               | 24,954 | \$                     | 1,392 | \$                     | 6,132   | \$  | (541) | \$                   | 35,450  | \$                               | 67,387  |
| Shares issued pursuant to public offering, net of issuance costs   | 2,500,000                     |                  | 9,769  |                        | -     |                        | -       |   | -     |                      | -       |                                  | 9,769   |
| Shares issued on exercise of stock options (note 23)   | 91,667                        |                  | 59     |                        | -     |                        | -       |   | -     |                      | -       |                                  | 59      |
| Issuance of warrants for common shares (note 8)  | -                             |                  | -      |                        | 148   |                        | -       |   | -     |                      | -       |                                  | 148     |
| Share-based compensation (note 23)   | 768,000                       |                  | 1,333  |                        | 186   |                        | -       |   | -     |                      | -       |                                  | 1,519   |
| Cumulative translation adjustment  | -                             |                  | -      |                        | -     |                        | -       |   | 150   |                      | -       |                                  | 150     |
| Reclassification of previously recorded revaluation gain of land, net of tax (note 7)                            | -                             |                  | -      |                        | -     |                        | (1,811) |   | -     |                      | -       |                                  | (1,811) |
| Net income   | -                             |                  | -      |                        | -     |                        | -       |   | -     |                      | 3,822   |                                  | 3,822   |
| Balance at December 31, 2017   | 42,242,612                    | \$               | 36,115 | \$                     | 1,726 | \$                     | 4,321   | \$  | (391) | \$                   | 39,272  | \$                               | 81,043  |
| Balance at January 1, 2018 (restated - note 4)   | 42,242,612                    | \$               | 36,115 | \$                     | 1,726 | \$                     | 4,321   | \$  | (391) | \$                   | 39,012  | \$                               | 80,783  |
| Shares issued pursuant to public offering, net of issuance costs  Shares issued pursuant to private placement of | 3,097,200                     |                  | 15,737 |                        | -     |                        | -       |   | -     |                      | -       |                                  | 15,737  |
| common shares, net of issuance costs   | 1,886,793                     |                  | 7,755  |                        | -     |                        | _       |   | -     |                      | _       |                                  | 7,755   |
| Shares issued on exercise of stock options (note 23)   | 365,733                       |                  | 434    |                        | (151) |                        | _       |   | _     |                      | -       |                                  | 283     |
| Share-based compensation (note 23)   | 50,334                        |                  | 831    |                        | 623   |                        | _       |   | _     |                      | -       |                                  | 1,454   |
| Cumulative translation adjustment  | =                             |                  | -      |                        | -     |                        | -       |   | (171) |                      | -       |                                  | (171)   |
| Net loss   | -                             |                  | -      |                        | -     |                        | -       |   | -     |                      | (5,145) |                                  | (5,145) |
| Balance at December 31, 2018   | 47,642,672                    | \$               | 60,872 | \$                     | 2,198 | \$                     | 4,321   | \$  | (562) | \$                   | 33,867  | \$                               | 100,696 |

 $\label{thm:companying} \textit{The accompanying notes are an integral part of these consolidated financial statements}.$ 

## $Consolidated \, Statements \, \, of \, (Loss) \, \, Income \, \, and \, \, Comprehensive \, \, Income \, \,$

## For the Years Ended December 31, 2018 and 2017

## (In thousands of United States dollars, except per share data)

|  | <br>2018      | <br>2017      |
|--|---------------|---------------|
| Sales (note 19)  | \$<br>150,000 | \$<br>158,406 |
| Cost of sales (note 15)                                | (140,282)     | (144,433)     |
| Change in biological asset (note 6)                    | (834)         | 265           |
| Selling, general and administrative expenses (note 15) | <br>(15,562)  | (15,413)      |
| Loss from operations                                   | (6,678)       | (1,175)       |
| Interest expense,net                                   | 2,407         | 2,695         |
| Foreign exchange loss (gain)                           | 1,047         | (26)          |
| Other income   | (131)         | (46)          |
| Share of (income) loss from joint venture (note 8)     | (2,381)       | 255           |
| Gain on disposal of assets (note 8)                    | <br>          | <br>(8,013)   |
| (Loss) income before income taxes                      | (7,620)       | 3,960         |
| (Recovery of) provision for income taxes (note 16)     | <br>(2,475)   | 138           |
| Net (loss) income                                      | \$<br>(5,145) | \$<br>3,822   |
| Basic (loss) income per share (note 21)                | \$<br>(0.11)  | \$<br>0.10    |
| Diluted (loss) income per share (note 21)              | \$<br>(0.11)  | \$<br>0.10    |
| Other comprehensive (loss) income:                     |               |               |
| Foreign currency translation adjustment                | (171)         | 150           |
| Gain on revaluation of land, net of tax (note 7)       | <br>          | <br>(1,811)   |
| Comprehensive (loss) income                            | \$<br>(5,316) | \$<br>2,161   |

The accompanying notes are an integral part of these consolidated financial statements.

## Consolidated Statements of Cash Flows

## For the Years Ended December 31,2018 and 2017

## (In thous ands of United States dollars)

|  |          | 2018   |    | 2017     |
|--|----------|--|----|----------|
| Cash flows from operating activities:                            |          | <u>.                                      </u> |    | _        |
| Net (loss) income  | \$       | (5,145)  | \$ | 3,822    |
| Adjustments to reconcile net (loss) income to net cash (used in) |          |  |    |          |
| provided by operating activities:                                |          |  |    |          |
| Depreciation and amortization                                    |          | 7,027  |    | 7,586    |
| Amortization of deferred charges                                 |          | -  |    | 73       |
| (Gain) loss on disposal of assets                                |          | -  |    | (8,013)  |
| Share of (income) loss from joint venture (note 8)               |          | (2,381)  |    | 255      |
| Interest expense   |          | 2,407  |    | 2,614    |
| Share-based compensation   |          | 1,454  |    | 1,519    |
| Deferred income taxes  |          | (2,906)  |    | 109      |
| Change in biological asset                                       |          | 834  |    | (265)    |
| Changes in non-cash working capital items (note 18)              |          | (3,550)  |    | (4,417)  |
| Net cash (used in) provided by operating activities              |          | (2,260)  |    | 3,283    |
| Cash flows from investing activities:                            |          |  |    |          |
| Purchases of property, plant and equipment                       |          | (3,093)  |    | (1,696)  |
| Note receivable to joint venture (note 8)                        |          | (10,462)                                       |    | -        |
| Proceeds from sale of land                                       |          | 65   |    | -        |
| Net cash used in investing activities                            |          | (13,490)                                       |    | (1,696)  |
| Cash flows from financing activities:                            |          |  |    |          |
| Proceeds from borrowings   |          | 7,000  |    | 7,306    |
| Repayments on borrowings   |          | (7,706)  |    | (14,320) |
| Interest paid on long-term debt                                  |          | (2,417)  |    | (2,614)  |
| Proceeds from issuance of common stock, net                      |          | 23,492   |    | 9,769    |
| Proceeds from exercise of stock options                          |          | 283  |    | 59       |
| Payments on capital lease obligations                            |          | (71)   |    | (59)     |
| Net cash provided by financing activities                        |          | 20,581   |    | 141      |
| Effect of exchange rate changes on cash and cash equivalents     |          | (2)  |    | (10)     |
| Increase in cash and cash equivalents                            |          | 4,829  |    | 1,718    |
| Cash and cash equivalents, beginning of year                     |          | 7,091  |    | 5,373    |
| Cash and cash equivalents, end of year                           | \$       | 11,920   | \$ | 7,091    |
|  |          | _  |    |          |
| Supplemental cash flowinformation:                               |          |  |    |          |
| Income taxes paid (recovered)                                    | \$       | 290  | \$ | (25)     |
| Supplemental disclosure of non-cash information:                 |          |  |    |          |
| Purchases of capital expenditures by financing capital lease     | \$       | _  | \$ | 190      |
| Issuance of warrants   | \$       |  | \$ | 148      |
| issuance of manunto  | <u> </u> |  | φ  | 146      |

The accompanying notes are an integral part of these consolidated financial statements.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### 1 NATURE OF OPERATIONS

Village Farms International, Inc. ("VFF" the parent company, together with its subsidiaries, the "Company") is incorporated under the *Canada Business Corporation Act.* VFF's principal operating subsidiaries as at December 31, 2018 are Village Farms Canada Limited Partnership ("VFCLP"), Village Farms, L.P. ("VFLP"), and VF Clean Energy, Inc ("VFCE"). The address of the registered office of VFF is 4700 80<sup>th</sup> Street, Delta, British Columbia, Canada, V4K 3N3. VFF owns a 50% equity interest in Pure Sunfarms Corp. ("Pure Sunfarms"), which is recorded as Investment in Joint Venture (note 8).

The Company's shares are listed on the Toronto Stock Exchange under the symbol VFF and are also listed in the United States on the Nasdaq Capital Market ("Nasdaq") under the symbol VFF (note 24).

The Company owns and operates sophisticated, highly intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells premium-quality tomatoes, bell peppers, and cucumbers. The Company also markets and sells third party produce through its subsidiaries. The Company, through its subsidiary VFCE, owns and operates a 7.0 MW power plant that generates electricity. In addition, the Company's joint venture, Pure Sunfarms, is a licensed producer and supplier of cannabis products to be sold to other licensed providers and provincial governments across Canada and internationally.

#### 2 BASIS OF PRESENTATION

#### **Basis of Presentation**

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

The consolidated financial statements were approved by the Board of Directors of the Company for issue on March 13, 2019. Management does not have the authority to amend the consolidated financial statements after the statements have been issued, without the approval by the Board of Directors of the Company. The preparation of consolidated financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies.

#### **Basis of Measurement**

The consolidated annual financial statements have been prepared on the historical cost basis except for the following material items on the consolidated statements of financial position:

- biological assets are measured at fair value less costs to sell;
- land is valued at fair market value; and
- marketable equity securities are measured at fair value through profit and loss.

#### **Functional and Presentation Currency**

The functional currency for each entity included in these consolidated financial statements is the currency of the primary economic environment in which the entity operates. These consolidated financial statements are presented in United States dollars ("U.S. dollars") which have been rounded to the nearest thousands, except per share amounts. Currency conversion to U.S. dollars is performed in accordance with IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

#### 3 SIGNIFICANT ACCOUNTING POLICIES, JUDGMENTS AND ESTIMATION UNCERTAINTY

The significant accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

#### Consolidation

The consolidated financial statements of the Company consolidate the accounts of VFF and its subsidiaries. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation.

#### Joint Venture

A joint venture is a contractual arrangement whereby the Company and other parties undertake an economic activity through a jointly controlled entity. Joint control exists when strategic, financial and operating policy decisions relating to the activities require the unanimous consent of the parties sharing control. Joint ventures are accounted for using the equity method and are recognized initially at cost. The Company recognizes its share of the post-acquisition income and expenses and equity movement

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

in the venture. If the cumulative losses exceed the carrying amount of the equity investment, they are first applied to any additional advances that are receivable from the joint venture to the extent of the total amount receivable. Additional losses are recognized only to the extent that there exists a legal or constructive obligation.

#### **Segment Reporting**

Operating segments are reported in a manner consistent with internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer ("CEO"). Based on the aggregation criteria in IFRS 8, *Operating Segments*, the Company has identified two operating segments, the Produce Business and the Energy Business.

### **Foreign Currency Translation**

Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rates in effect at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated to the functional currency at the exchange rate in effect when the fair value was determined. Foreign currency differences are generally recognized in net income. Non-monetary items that are measured based on historical cost in a foreign currency are translated to the functional currency using the exchange rate in effect at the date of the transaction giving rise to the item.

#### **Financial Instruments**

Financial assets and liabilities are recognized when the Company becomes party to the contractual provisions of the financial instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expired.

Financial assets and liabilities are offset and the net amount is reported on the consolidated statements of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

#### Classification and Measurement

The Company has assessed the classification and measurement of its financial assets and financial liabilities under IFRS 9 and has summarized the original measurement categories under IAS 39 and the new measurement categories under IFRS 9 in the following table:

|                              | Measurement                       | Category                          |
|------------------------------|-----------------------------------|-----------------------------------|
|                              | Original (IAS 39)                 | New (IFRS 9)                      |
| Financial Assets:            |                                   |                                   |
| Cash                         | Amortized cost                    | Amortized cost                    |
| Trade receivables            | Amortized cost                    | Amortized cost                    |
| Marketable equity securities | Available-for-sale                | Fair value through other          |
|                              |                                   | comprehensive income              |
| Other financial assets       | Amortized cost                    | Amortized cost                    |
| Financial Liabilities:       |                                   |                                   |
| Trade payables               | Amortized cost                    | Amortized cost                    |
| Debt                         | Amortized cost                    | Amortized cost                    |
| Derivative instruments       | Fair value through profit or loss | Fair value through profit or loss |
| Other financial liabilities  | Amortized cost                    | Amortized cost                    |

There has been no change in the carrying value of our financial instruments or to previously reported figures as a result of changes to the measurement categories in the table noted above.

#### **Impairment of Financial Assets**

Prior to January 1, 2018, at each reporting date, the Company assessed whether there was objective evidence that a financial asset was impaired. The criteria used to determine if objective evidence of an impairment loss exists include:

i) significant financial difficulty of the obligor;

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

- ii) delinquencies in interest or principal payments; and
- iii) it becomes probable that the borrower will enter bankruptcy or other financial reorganization.

If such evidence existed, the Company recognized an impairment loss as follows:

- i) Financial assets carried at amortized cost: The loss equaled the difference between the amortized cost of the loan or receivable and the present value of the estimated future cash flows, discounted using the instrument's original effective interest rate. The carrying amount of the asset was reduced by this amount either directly or indirectly through the use of an allowance account.
- ii) Available-for-sale financial assets: The impairment loss equaled the difference between the original cost of the asset and its fair value at the measurement date, less any impairment losses previously recognized in the consolidated statements of (loss) income. This amount represented the cumulative loss in accumulated other comprehensive income that was reclassified to net income.

Subsequent to January 1, 2018, the Company assesses all information available, including, on a forward-looking basis, the expected credit losses associated with its assets carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. To assess whether there is a significant increase in credit risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition based on all information available, and reasonable and supportive forward-looking information. For trade receivables only, the Company applies the simplified approach as permitted by IFRS 9 which requires expected lifetime losses to be recognized from initial recognition of the receivables.

#### **Cash and Cash Equivalents**

Cash and cash equivalents consist of cash deposits held with banks, and other highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less.

#### **Trade Receivables**

Trade receivables are measured at amortized cost, net of allowance for expected credit losses. Credit is extended based on an evaluation of a customer's financial condition. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time accounts are past due, the Company's previous loss history and the customer's current ability to pay its obligation to the Company. Trade receivables are recorded net of lifetime expected credit losses.

#### **Inventories**

Inventories refer to deferred crop costs and other supplies and packaging which are incurred to date on current production and are not defined as a biological asset. Inventories of Company-grown produce consist of raw materials, labour and overhead costs incurred less costs charged to cost of sales throughout the various crop cycles, which end at various times throughout the year. Growing crops are accounted for in accordance with the Company's policy on biological assets. Cost of sales is based on estimated costs over the crop cycle allocated to both actual and estimated future yields at each period-end date.

The carrying value of agricultural produce is its fair value less costs to sell and complete at the date of harvest and is presented with biological asset on the consolidated statements of financial position. Supplies and packaging are recorded at the lower of cost or replacement cost. The cost of produce inventory purchased from third parties is valued at the lower of cost or net realizable value.

#### **Biological Asset**

Biological asset consists of the Company's produce on the vines at year-end. Measurement of the biological asset begins six weeks prior to harvest as management at this point has visibility on production and expected sales and it is probable that future economic benefits associated with the asset will flow to the entity. Costs related to the crop prior to this point are presented in deferred crop costs (inventories). The produce on the vine is measured at fair value less costs to sell and costs to complete, with any change therein recognized in income. Costs to sell include all costs that would be necessary to sell the assets, including finishing and transportation costs.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### **Property, Plant and Equipment**

#### Recognition and measurement

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, except for land. Until the fiscal year ended December 31, 2016, land had been stated at cost, and is now stated at fair value and will be revalued every three years by an independent external appraiser. Any revaluation increase arising on appraisal of land is recognized in other comprehensive income on the consolidated statements of (loss) income and revaluation surplus on the statements of financial position. Any revaluation decrease arising on appraisal of land is also charged to other comprehensive income and, to the extent of any credit balance existing, debited to revaluation surplus in equity with the excess recognized in net income or loss,

Property, plant and equipment costs include expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located, and borrowing costs.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

The gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment, and is presented net within gain/loss on disposal of assets in the consolidated statements of (loss) income.

#### Depreciation

Depreciation is based on the cost of an asset less its residual value. Significant components of individual assets are assessed, and if a component has a useful life that is different from the remainder of that asset, that component is depreciated separately.

Depreciation expense is recognized on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Land is not depreciated. The estimated useful lives of the class of assets for the current and comparative periods are as follows:

| Classification                  | Estimated Useful Lives |
|---------------------------------|------------------------|
| Leasehold and land improvements | 5-20 years             |
| Greenhouses and other buildings | 4-30 years             |
| Greenhouse equipment            | 3-30 years             |
| Machinery and equipment         | 3-12 years             |

Construction in process reflects the cost of assets under construction, which are not depreciated until placed into service.

#### **Impairment of Non-Financial Assets**

Property, plant and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of testing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or "CGUs"). An impairment loss is recognized for the amount, if any, by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use (being the present value of the expected future cash flows of the relevant asset or CGUs).

#### **Leased Assets**

Leases where the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. Upon initial recognition, the leased asset is measured at an amount equal to the lower of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Other leases are operating leases and rent expenses are recognized in the Company's consolidated statements of (loss) income.

#### **Borrowing Costs**

Borrowing costs attributable to the acquisition, construction or production of qualifying assets are added to the cost of those assets, until such time as the assets are substantially ready for their intended use. All other borrowing costs are recognized

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

initially at fair value. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of (loss) income over the year of the borrowings using the effective interest method.

#### **Revenue Recognition**

Prior to January 1, 2018, revenue from the sale of produce in the course of ordinary activities was measured at the fair value of the consideration received or receivable, net of returns, trade discounts and volume rebates. Revenue from the production and sale of power was measured at the fair value of the consideration received or receivable. Revenue was recognized when persuasive evidence existed that the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration was probable, the associated costs and possible return of goods could be estimated reliably, there was no continuing management involvement with the goods, and the amount of revenue could be measured reliably. If it was probable that discounts would be granted and the amount could be measured reliably, then the discount was recognized as a reduction of revenue as the sales were recognized. The timing of the transfer of risks and rewards occurred at the time the produce had been successfully delivered, the risk of loss had passed to the customer, and collectability was reasonably assured.

The Company adopted IFRS 15, Revenue from Contracts with Customers ("IFRS 15") on January 1, 2018 using the modified retrospective transition approach and now recognizes revenue when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. In order to achieve this core principle, the Company applies a five-step process. As part of this process, it analyzes the performance obligations in a customer contract and estimates the consideration it expects to receive. The evaluation of performance obligations requires that the Company identifies the promised goods and services in the contract. For contracts that contain more than one promised good and service, the Company then must determine whether the promises are capable of being distinct and if they are separately identifiable from other promises in the contract.

#### **Income Taxes**

The tax expense for the year comprises current and deferred tax. Tax is recognized in the consolidated statements of (loss) income, except to the extent that it relates to items recognized in other comprehensive income or directly in equity.

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the consolidated statements of financial position dates in the relevant tax jurisdiction. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of the amounts expected to be paid to the tax authorities.

Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted at the consolidated statements of financial position dates and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Offsetting of deferred income tax assets and liabilities occurs only when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

#### **Share-Based Compensation**

The Company grants stock options and performance-based restricted share units ("RSUs") to certain employees and directors.

Stock options generally vest over three years (33% per year following the grant date) and expire after ten years. Each tranche in an award is considered a separate award with its own vesting period. The fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche's vesting period by increasing contributed surplus based on the number of awards expected to vest. The number of awards expected to vest is reviewed at least annually, with any impact recognized immediately.

The RSUs granted are expected to be settled using the Company's own equity and issued from treasury. The equity-settled share-based compensation is measured at the fair value of the Company's common shares as at the grant date in accordance with the terms of the RSU Plan. The fair value determined at the grant date is charged to income when performance based vesting conditions are met, based on the estimate of the number of RSUs that will eventually vest and be converted to common shares, with a corresponding increase in equity.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### **Provisions**

Provisions, where applicable, are recognized in accrued liabilities when the Company has a present legal or constructive obligation as a result of past events, it is more likely than not that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at management's best estimate of the expenditure required to settle the obligation at the end of the reporting period, and are discounted to present value where the effect is material.

#### (Loss) Income Per Share

Basic income per share are computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted income per share. Under this method, the weighted average number of common shares outstanding assumes that the proceeds to be received on the exercise of dilutive share options are applied to repurchase common shares at the average market price for the period. Share options are dilutive when the average market price of the common shares during the period exceeds the exercise price of the options.

#### **Significant Accounting Judgments and Estimation Uncertainties**

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. These estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in future periods.

Critical accounting estimates and judgments

#### i) Estimated useful lives of property, plant and equipment

Management estimates the useful lives of property, plant and equipment based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for depreciation of property, plant and equipment for any period are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of physical wear and tear, technical or commercial obsolescence and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company's property, plant and equipment in the future.

#### ii) Biological asset

The fair value of the biological asset is derived using a discounted cash flow model. Management estimates the sales price of produce on the vine by utilizing actual sales prices for the first six weeks following the end of the reporting period and estimates the costs to sell and complete by projecting yields and crop, packaging, and transportation costs. The estimated costs are subject to fluctuations based on the timing of prevailing growing conditions and market conditions. Management has also used judgment in determining the point at which biological transformation has occurred to the point that they expect it is probable that future economic benefits associated with the crop will flow to the Company.

#### iii) Inventories and cost of sales

Cost of sales is based upon incurred costs, and estimated costs to be incurred, of each crop allocated to both actual and estimated future yields over each crop cycle. The estimates of future yields are reviewed at each reporting period for accuracy. However, numerous factors such as weather, diseases and prevailing market conditions can impact the estimation of pricing, costs, and future yields. The estimated costs to be incurred are based on references to historical costs and updated for discussions with suppliers and senior management. Inventories include the actual cost of the crop not yet defined as a biological asset, packaging supplies, and purchased produce, less the amounts that have been expensed in cost of sales.

#### iv) Income taxes and deferred income tax assets or liabilities

Management uses judgment and estimates in determining the appropriate rates and amounts in recording deferred taxes, giving consideration to timing and probability. Actual taxes could vary significantly from these estimates as a result of future events, including changes in income tax law or the outcome of reviews by tax authorities and related appeals. The resolution of these uncertainties and the associated final taxes may result in adjustment to the Company's tax assets and tax liabilities. The recognition of deferred income tax assets is subject to judgment and estimation over whether these amounts can be realized.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### 4 CHANGES IN ACCOUNTING POLICIES

The Company has adopted the following new and revised standards and changes in accounting policies, along with any consequential amendments as at January 1, 2018. These changes were made in accordance with the applicable transitional provisions.

IFRS 9, Financial Instruments replaced the current IAS 39, Financial Instruments Recognition and Measurement. This standard sets out revised guidance for classifying and measuring financial assets and liabilities, introduces a new expected credit loss model for calculating impairment of financial assets and includes a reformed approach to hedge accounting. The standard also requires that when a financial liability at amortized cost is modified or exchanged, and such modification or exchange does not result in de-recognition, that the adjustment to the amortized cost of the financial liability is recognized in profit or loss. IFRS 9 was adopted without restating comparative information. The reclassifications arising from the new rules are therefore not reflected in the statement of financial position as at December 31, 2017, but are recognized in the opening statement of financial position on January 1, 2018.

Following the adoption of IFRS 9, the Company could no longer defer and amortize financing fees that resulted from the refinancing of borrowings in periods prior to January 1, 2018. As a result, the Company has restated the beginning balances noted in the table below to properly account for \$260 of financing fees in accordance with IFRS 9. The standard was applied retrospectively therefore approximately \$260 of deferred financing costs, net of accumulated amortization, remain netted against long-term debt on the consolidated statement of financial position, as at December 31, 2017.

The following table shows the adjustments recognized for each individual line item.

| Statement of Financial Position (extract) | As | ber 31, 2017<br>originally<br>resented | <br>FRS 9   |    | ary 1, 2018<br>estated |
|---|----|--|-------------|----|------------------------|
| Non-current liabilities                   |    |  |             |    |                        |
| Long-term debt                            | \$ | 35,760                                 | \$<br>260   | \$ | 36,020                 |
| Total liabilities                         |    | 61,298                                 | <br>260     | '  | 61,558                 |
| Shareholders' Equity                      |    |  |             |    |                        |
| Retained earnings                         |    | 39,272                                 | (260)       |    | 39,012                 |
| Total shareholders' equity                | \$ | 81,043                                 | \$<br>(260) | \$ | 80,783                 |

IFRS 15, replaces IAS 18, *Revenue*, and IAS 11, *Construction Contracts*, and the related Interpretations on revenue recognition. IFRS 15 establishes a single comprehensive model for recognizing revenues from contracts with customers. The standard requires revenue to be recognized in a manner that depicts the transfer of promised goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for transferring those goods and services.

The Company generates its revenue through the sale of produce, with standard shipping terms and discounts, and through the production and sale of power.

The Company's produce revenue transactions consist of single performance obligations to transfer promised goods. Quantities to be delivered to the customer are determined at a point near the date of delivery through purchase orders it receive from the customer. The Company recognizes revenue when it has fulfilled a performance obligation, which is typically when the customer receives the goods and its performance obligation is complete. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring product. The amount of revenue recognized is reduced for estimated returns and other customer credits, such as discounts and rebates, based on the expected value to be realized. Payment terms are consistent with terms standard to the markets the Company serves. The Company maintains an allowance for doubtful accounts for the loss that would be incurred if a customer was unable to pay amounts due. The Company initially estimates the allowance required at the time of revenue recognition based on historical experience and makes changes to the allowance based on various factors, including changes in the customer's financial condition or payment patterns.

The Company sells electricity to British Columbia Hydro and Power Authority. Revenues are recognized as the electricity is delivered to/consumed by the customer and is based on contractual usage rates and meter readings that measure electricity consumption.

The Company adopted IFRS 15, as of January 1, 2018, using the modified retrospective transition method, which involves not restating periods prior to the date of initial application. The application of IFRS 15 required no change in amounts recognized

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

in the Company's consolidated financial statements for the year ended December 31, 2018, as the amount and timing of substantially all of its revenues is, and will continue to be, recognized at delivery. Disclosures required by IFRS 15 have been included in the financial statements.

#### **Accounting Standards Issued But Not Yet Adopted**

IFRS 16, Leases, issued in January 2016, replaces IAS 17, Leases, and related Interpretations. IFRS 16 establishes the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract, i.e. the customer (lessee) and the supplier (lessor). IFRS 16 requires a lessee to recognize a right-of-use asset representing its right to use the underlying leased asset and a corresponding lease liability representing its obligation to make lease payments for all leases. A lessee recognizes the related expense as depreciation on the right-of-use asset and interest on the lease liability. Short-term (less than 12 months) and low-value asset leases are exempt from these requirements. IFRS 16 may be implemented using a retrospective approach or a modified retrospective approach, which permits the use of certain practical expedients upon transition. The Company expects to use the modified retrospective method upon transition with no restatement of comparative financial information. Under this approach, the Company will recognize the cumulative effect of initially applying IFRS 16 as an adjustment to the opening balance of retained earnings at January 1, 2019. The Company will recognize a lease liability at the present value of the remaining lease payments discounted using the lease's incremental borrowing rate at January 1, 2019 and a right-of-use asset at its carrying amount as if IFRS 16 had been applied since the commencement date but discounted using the Company's incremental borrowing rate at January 1, 2019. Management expects that IFRS 16 will result in the following: a) an increase in assets and liabilities as fewer leases will be expensed as payments are made; b) an increase in depreciation expenses; and c) an increase in cash flow from operating activities as these lease payments will be recorded as financing outflows in the cash flow statements.

Amendments to IFRS 11, *Joint Arrangements*, and IAS 28, *Investments in Associates and Joint Ventures* establishes the criteria for accounting for joint ventures. Investments in joint ventures are accounted for using the equity method. The equity method involves recording the initial investment at cost and subsequently adjusting the carrying value of the investment for the proportionate share of the profit or loss, other comprehensive income or loss and any other changes in the joint venture's net assets such as dividends. At each consolidated statement of financial position date, the Company will consider whether there is objective evidence that its investment in the joint venture is impaired. If there is such evidence of impairment, the Company will determine the amount of the impairment and a loss will be recorded in the consolidated statement of (loss) income. Amendments to IFRS 11 is effective for annual periods beginning on or after January 1, 2019. Management is currently assessing the impact of IFRS 11 on its consolidated financial statements.

December 31 2018

December 31, 2017

#### 5 INVENTORIES

|                                      | Deceii | iber 51, 2018 | Decem | ber 51, 2017 |
|--------------------------------------|--------|---------------|-------|--------------|
| Deferred crop costs                  | \$     | 24,649        | \$    | 19,070       |
| Purchased produce inventory          |        | 643           |       | 396          |
| Biological asset adjustment (note 6) |        | (2,871)       |       | (2,212)      |
| Spare parts inventory                |        | 64            |       | 55           |
|                                      | \$     | 22,485        | \$    | 17,309       |

The cost of inventories recognized as expense and included in cost of sales for the year ended December 31, 2018 amounted to \$114,236 (2017 - \$120,509). The biological asset adjustment reclassifies actual costs incurred for the biological asset from inventories to biological asset on the consolidated statements of financial position.

#### 6 BIOLOGICAL ASSET

Information about the biological asset presented on the consolidated statements of financial position and in the consolidated statements of (loss) income is as follows:

|  | mber 31,<br>2018 | December 31, 2017 |       |  |
|--|------------------|-------------------|-------|--|
| Estimated sales value - biological asset   | \$<br>8,004      | \$                | 7,937 |  |
| Less Estimated remaining costs to complete | 3,304            |                   | 3,043 |  |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

| Estimated selling costs  | <br>470            | <br>489        |
|--|--------------------|----------------|
| Fair value of biological asset less costs to sell<br>Less actual costs (note 5)                    | <br>4,230<br>2,871 | 4,405<br>2,212 |
| Increase in fair value of biological asset over cost<br>Fair value over cost of harvested and sold | 1,359              | 2,193          |
| biological asset - beginning of year   | <br>2,193          | <br>1,928      |
| Change in biological asset   | \$<br>(834)        | \$<br>265      |

## 7 PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

|   | Land     | Leasehold<br>and land<br>improve-<br>ments | and land  |           | Construction in process | Total      |
|---|----------|--|-----------|-----------|-------------------------|------------|
| Year ended December 31, 2017            | <u> </u> |  | Buildings | Equipment | m process               | 10141      |
| Opening net book value                  | \$11,864 | \$ 1,692                                   | \$ 50,517 | \$ 31,767 | \$ 295                  | \$ 96,135  |
| Additions/transfers                     | ·        | -  | (416)     | 789       | 1,412                   | 1,785      |
| Additions-Capital Lease                 | -        | _  | -         | 191       | , <u>-</u>              | 191        |
| Placed in service                       | -        | -  | -         | 1,071     | (1,164)                 | (93)       |
| Disposals                               | (2,752)  | -  | (5,524)   | (4,694)   | (75)                    | (13,045)   |
| Accum deprec on disposal                | -        | _  | 1,601     | 2,521     | -                       | 4,122      |
| Depreciation expense                    | -        | (95)                                       | (2,858)   | (4,633)   | -                       | (7,586)    |
| Foreign currency translation adjustment | _        | _  | 24        | 221       | -                       | 245        |
| Closing net book value                  | \$ 9,112 | \$ 1,597                                   | \$ 43,344 | \$ 27,233 | \$ 468                  | \$ 81,754  |
| At December 31, 2017                    |          |  |           |           |                         |            |
| Cost                                    | \$ 9,112 | \$ 3,820                                   | \$ 77,029 | \$ 63,237 | \$ 468                  | \$ 153,666 |
| Accumulated depreciation                | -        | (2,223)                                    | (33,685)  | (36,004)  | -                       | (71,912)   |
| Net book value                          | \$ 9,112 | \$ 1,597                                   | \$ 43,344 | \$ 27,233 | \$ 468                  | \$ 81,754  |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

| Year ended December 31, 2018 |             |             |              |              |    |         |               |
|------------------------------|-------------|-------------|--------------|--------------|----|---------|---------------|
| Opening net book value       | \$<br>9,112 | \$<br>1,597 | \$<br>43,344 | \$<br>27,233 | \$ | 468     | \$<br>81,754  |
| Additions/transfers          | -           | -           |              | 3,012        |    | 3,116   | 6,128         |
| Placed in service            | -           | -           | -            |              | (  | (3,035) | (3,035)       |
| Disposals                    | (65)        | -           | -            | (565)        |    | -       | (630)         |
| Accum deprec on disposal     | -           | -           | -            | 565          |    | -       | 565           |
| Depreciation expense         | -           | (85)        | (2,604)      | (4,338)      |    | -       | (7,027)       |
| Foreign currency translation |             |             |              |              |    |         |               |
| adjustment                   | -           | -           | (26)         | (253)        |    | 3       | (276)         |
| Closing net book value       | \$<br>9,047 | \$1,512     | \$<br>40,714 | \$<br>25,654 | \$ | 552     | \$<br>77,479  |
| At December 31, 2018         |             |             |              |              |    |         |               |
| Cost                         | \$<br>9,047 | \$3,820     | \$<br>77,003 | \$<br>65,996 | \$ | 552     | \$<br>156,418 |
| Accumulated depreciation     | -           | (2,308)     | (36,289)     | (40,342)     |    | -       | (78,939)      |
| Net book value               | \$<br>9,047 | \$<br>1,512 | \$<br>40,714 | \$<br>25,654 | \$ | 552     | \$<br>77,479  |

Depreciation related to the greenhouse facilities and equipment is expensed in cost of sales. Land is the only item of property, plant and equipment that is stated at fair values. As at December 31, 2017, land, greenhouse buildings, and greenhouse equipment at Delta 3 were contributed as the Company's investment in the joint venture transaction (note 8). The revaluation surplus related to Delta 3 of \$1.8 million, net of taxes, that was previously recorded as a component of equity, was reclassified and included as part of the gain on disposal of assets recorded in the consolidated statements of (loss) income.

#### 8 INVESTMENT IN JOINT VENTURE

On June 6, 2017, the Company entered into an agreement to form Pure Sunfarms Corp. ("Pure Sunfarms"), a B.C. corporation, with Emerald Health Therapeutics Inc. ("Emerald"). The purpose of Pure Sunfarms is to pursue large-scale cannabis production in Canada. Village Farms has a 50% ownership interest in Pure Sunfarms in the form of common shares. The Company has concluded that the agreement constitutes a joint arrangement where joint control is shared with Emerald and therefore has accounted for Pure Sunfarms in accordance with IFRS 11 and IAS 28, using the equity method.

In conjunction with the formation of Pure Sunfarms, Village Farms contributed the rights to lease and purchase the Delta 3 land and greenhouse facility to the joint venture. The contribution of the rights has been accounted for as a reduction of the land and greenhouse facility in exchange for the investment in Pure Sunfarms Corp. It was determined that the land and greenhouse facility had a fair value of \$14.9 million (CA\$20 million) at the date of contribution. The fair value of the land was determined through an appraisal performed by an independent valuator. The fair value of the greenhouse was determined using the replacement cost model adjusted for the age of the greenhouse. This was a non-cash transaction. The Company recognized a gain of \$8.0 million on the contribution of the land and greenhouse. The Company had previously recorded a fair value increase on the Delta 3 land (2016 - \$2.1 million), which was recorded in accumulated other comprehensive income, net of taxes of \$1.8 million. As a result of the contribution of the Delta 3 land, this amount has been recycled to the consolidated statements of (loss) income, and has been included in the gain noted above.

As part of the transaction, Village Farms incurred related transaction costs of \$1.1 million (CA\$1.4 million), which have been added to the amount of the investment in Pure Sunfarms Corp. in accordance with IAS 28. Included in these costs are 300,000 common share purchase warrants valued at \$148 (CA\$192), issued to an affiliate of a Canadian financial institution as partial consideration for services related to the joint venture agreement. As at December 31, 2018 the Investment in Joint Venture of \$18.1 million (December 31, 2017 - \$15.7 million) is recorded in the consolidated statement of financial position. For the year ended December 31, 2018, the Company's share of net income from joint venture totaled \$2,381 (CA\$3,084) (2017 - \$255), which is recorded in the consolidated statement of loss.

On July 5, 2018, the Company and Emerald Health Therapeutics Canada Inc. (a subsidiary of Emerald) (together, the "Shareholders") entered into a Shareholder Loan Agreement (the "Loan Agreement") with Pure Sunfarms, whereby, as at December 31, 2018, the Shareholders had each contributed CA\$13,000 (US\$9,959) the form of a demand loan to Pure Sunfarms. The loan amounts will initially bear simple interest at the rate of 8% per annum, calculated semi-annually. Interest will accrue and be payable upon demand being made by both Shareholders (see note 13).

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

The Company's share of the joint venture consists of the following (in \$000's of USD):

| Balance, January 1, 2018     | \$<br>15,727 |
|------------------------------|--------------|
| Share of income for the year | <br>2,381    |
| Balance, December 31, 2018   | \$<br>18,108 |

## Summarized financial information of Pure Sunfarms (in \$000's of CAD):

| Summarized financial information of Pure Sunfarms (in \$000) | )'s of CAD): |               |        |              |
|--|--------------|---------------|--------|--------------|
|  | Decem        | ber 31, 2018  | Decem  | ber 31, 2017 |
| Current assets   |              |               |        |              |
| Cash and cash equivalents                                    | \$           | 2,362         | \$     | 2,907        |
| Trade receivables  |              | 1,312         |        | -            |
| Inventory  |              | 8,356         |        | 25           |
| Biological asset   |              | 7,388         |        | _            |
| Other current assets   |              | 996           |        | 210          |
| Non-current assets   |              | 67,263        |        | 23,384       |
| Current liabilities  |              | ,             |        | ,            |
| Trade payables   |              | (9,361)       |        | (253)        |
| Due to joint venture partners                                |              | (26,523)      |        | -            |
| Other current liabilities                                    |              | (3,582)       |        | (918)        |
| Non-current liabilities                                      | <del></del>  | (2,688)       |        |              |
| Net assets   | \$           | 45,523        | \$     | 25,355       |
|  | Decem        | aber 31, 2018 | Decemi | ber 31, 2017 |
| Reconciliation of net assets:                                | Весен        | 1001 31, 2010 | Decem  | bei 31, 2017 |
| Accumulated deficit  | \$           | 5,523         | \$     | (645)        |
| Contributions from joint venture partners                    | Ψ            | 40,000        | Ψ      | 26,000       |
| Net assets   | \$           | 45,523        | \$     | 25,355       |
| Net assets   | Ψ            | 45,323        | Φ      | 25,555       |
|  | Ye           | ar Ended      | Yea    | ar Ended     |
|  | Decem        | ber 31, 2018  | Decem  | ber 31, 2017 |
| Revenue  | \$           | 4,917         | \$     | -            |
| Cost of sales*   |              | (1,542)       |        | -            |
| Selling, general and administrative expenses                 |              | (3,386)       |        | (880)        |
| Change in fair value of bio-asset                            |              | 8,785         |        | -            |
| Income (loss) from operations                                |              | 8,774         |        | (880)        |
| Interest expense, net  |              | (97)          |        | -            |
| Foreign exchange loss  |              | (234)         |        | (4)          |
| Other income, net  |              | 24            |        | -            |
| Income (loss) before taxes                                   |              | 8,467         |        | (884)        |
| (Provision for) recovery of income taxes                     |              | (2,298)       |        | 239          |
| Net income (loss)  | \$           | 6,169         | \$     | (645)        |
|  |              |               | -      |              |

<sup>\*</sup>Included in cost of sales is CA\$276 (US\$206) of amortization expense.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### 9 OTHER ASSETS

The following table summarizes the components of other assets:

|                                  | Decemb | oer 31, 2018 | <u>Decemb</u> | oer 31, 2017 |
|----------------------------------|--------|--------------|---------------|--------------|
| Patronage stock                  | \$     | 386          | \$            | 437          |
| Note receivable (note 13)        |        | 64           |               | 70           |
| Security deposits                |        | 540          |               | 538          |
| Cash surrender value - insurance |        | 929          |               | 924          |
| Other                            |        | 288          |               | 35           |
| Total                            | \$     | 2,207        | \$            | 2,004        |

#### 10 DEBT

|  | <u>December 31, 2018</u> |         | December 31, 2017 |         |
|--|--------------------------|---------|-------------------|---------|
| Long-term debt:                              |                          |         |                   |         |
| Opening balance                              | \$                       | 38,380  | \$                | 45,534  |
| IFRS adjustment for deferred financing fees  |                          | 260     |                   |         |
| Proceeds from long-term debt                 |                          | -       |                   | 306     |
| Repayment of debt                            |                          | (2,738) |                   | (7,320) |
| Foreign currency translation                 |                          | (43)    |                   | 120     |
| Closing balance                              | \$                       | 35,859  | \$                | 38,640  |
| Current portion                              | \$                       | 3,414   | \$                | 2,620   |
| Non-current portion                          |                          | 32,445  |                   | 36,020  |
| Less: Unamortized deferred transaction costs |                          |         |                   | (260)   |
|  | \$                       | 35,859  | \$                | 38,380  |

The Company has a Term Loan financing agreement with a Canadian creditor ("FCC Loan"). The non-revolving variable rate term loan has a maturity date of May 1, 2021 and a balance of \$34,385 as at December 31, 2018. The outstanding balance is repayable by way of monthly installments of principal and interest based on an amortization period of 15 years, with the balance and any accrued interest to be paid in full on May 1, 2021. As at December 31, 2018, borrowings under the FCC Loan agreement are subject to an interest rate of 7.082% (December 31, 2017 - 5.885%) which is determined based on the Company's Debt to EBITDA ratio and the applicable LIBOR rate.

The Company's subsidiary VFCE has a loan agreement with a Canadian Chartered Bank that includes a non-revolving fixed rate loan of CA\$3.0 million with a maturity date of June 2023 and fixed interest rate of 4.98%. As at December 31, 2018, the balance was US\$1,279 (December 31, 2017 - US\$1,658). The loan agreement also includes an uncommitted, non-revolving credit facility for up to CA\$300 to cover Letters of Guarantee issued by the bank on behalf of the Company, with a maximum term of 365 days, renewable annually. The loan agreement also includes an uncommitted credit facility for up to CA\$700 to support financing of certain capital expenditures. The Company received an initial advance of CA\$250 in October 2017. Each advance is to be repaid on a five-year, straight-line amortization of principal, repaid in monthly installments of principal plus interest at an interest rate of CA\$ prime rate plus 200 basis points. As at December 31, 2018, the balance was US\$138 (December 31, 2017 - \$192).

The Company has a line of credit agreement with a Canadian Chartered Bank ("Operating Loan"). The revolving Operating Loan has a line of credit up to CA\$13,000 and variable interest rates with a maturity date on May 31, 2021, and is subject to margin requirements stipulated by the bank. As at December 31, 2018, US\$2,000 was drawn on this facility (December 31, 2017 - \$nil), which is available to a maximum of CA\$13,000, less outstanding letters of credit totaling US\$261 and CA\$38.

The Company's borrowings ("Credit Facilities") are subject to certain positive and negative covenants. As at December 31, 2018 the Company was in compliance with all covenants on its Credit Facilities with the exception of two of its FCC Loan covenants. The Company received a waiver for its Debt Service Coverage and Debt to EBITDA covenants as at December 31, 2018.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

Accrued interest payable on the credit facilities and loans as at December 31, 2018 was \$184 (December 31, 2017 - \$193) and these amounts are included in accrued liabilities in the statement of financial position.

As security for the FCC Loan, the Company has provided promissory notes, a first mortgage on the VFF-owned greenhouse properties (excluding the Delta 3 and Delta 2 greenhouse facilities), and general security agreements over its assets. In addition, the Company has provided full recourse guarantees and has granted security therein. The carrying value of the assets and securities pledged as collateral as at December 31, 2018 was \$114,554 (December 31, 2017 – \$120,815).

As security for the Operating Loan, the Company has provided promissory notes and a first priority security interest over its accounts receivable and inventory. In addition, the Company has granted full recourse guarantees and security therein. The carrying value of the assets pledged as collateral as at December 31, 2018 was \$38,007 (December 31, 2017 - \$32,883).

The aggregate annual maturities of long-term debt for the next five years and thereafter are as follows:

| 2019       | \$<br>3,414  |
|------------|--------------|
| 2020       | 3,409        |
| 2021       | 28,551       |
| 2022       | 330          |
| 2023       | 155          |
| Thereafter | <br>-        |
|            | \$<br>35,859 |

#### 11 COMMITMENTS

#### **Operating Leases**

The Company has entered into certain operating lease commitments for land, office space and equipment through 2024. The future minimum lease payments for the next five years and thereafter are as follows:

| 2019       | \$<br>1,253 |
|------------|-------------|
| 2020       | 1,039       |
| 2021       | 1,052       |
| 2022       | 841         |
| 2023       | 618         |
| Thereafter | 261         |
|            | \$<br>5,064 |

The Company made payments of \$1,732 during the year ended December 31, 2018 (2017 - \$1,682). Payments include common area amounts and fees paid to the lessors.

#### 12 FINANCIAL INSTRUMENTS

The following table summarizes the carrying and fair value of the Company's financial instruments:

|                             | Dece | Decem  | December 31, 2017 |        |  |
|-----------------------------|------|--------|-------------------|--------|--|
| Cash and cash equivalents   | \$   | 11,920 | \$                | 7,091  |  |
| Trade receivables           | \$   | 11,292 | \$                | 11,259 |  |
| Other financial assets      | \$   | 11,659 | \$                | 2,491  |  |
| Other financial liabilities | \$   | 57,198 | \$                | 56,718 |  |

Financial assets and liabilities are recognized on the consolidated statements of financial position at fair value in a hierarchy that is based on significance of the inputs used in making the measurements. The levels in the hierarchy are:

- Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices)

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

Level 3 - Inputs for the asset or liability that are not based on observable market data (i.e., unobservable inputs).

At December 31, 2018 and 2017, the Company's financial instruments included cash and cash equivalents, trade receivables, notes receivable, other receivables, patronage stock, accounts payable, other current liabilities and notes payable. Due to the short-term maturities of cash and cash equivalents, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate fair value at the respective balance sheet dates. The carrying value of the notes receivable and notes payable approximate their fair value based on a comparison with the prevailing market interest rates. The fair values of the Company's notes receivable and notes payable are level 2 measurements in the fair value hierarchy. All other financial assets and liabilities are level 1. None were classified as level 3.

There were no financial instruments categorized as Level 2 or 3 as at December 31, 2018 and 2017. There were no transfers of assets or liabilities between levels during the years ended December 31, 2018 and 2017.

Interest income, expense and gains and losses from loans, receivables and other financial liabilities are recognized in the consolidated statements of (loss) income. The following table summarizes interest income and expense for the years ended December 31:

|   | 2  | 2018  | 2  | 2017  |
|---|----|-------|----|-------|
| Interest income earned on cash and cash equivalents | \$ | 311   | \$ | -     |
| Interest expense from other financial liabilities   | \$ | 2,718 | \$ | 2,695 |

#### Management of financial risks

The Company, through its financial assets and liabilities, is exposed to various risks. The following provides a measurement of some of these risks as at December 31, 2018 and 2017. The Company uses financial instruments only for risk management purposes, not for generating trading profit.

#### i) Credit risk

Credit risk is the risk that the Company will incur a loss due to the failure by its customers or other parties to meet their contractual obligations. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, trade receivables and other receivables. The Company limits its exposure to credit risk by placing its cash and cash equivalents with high credit quality financial institutions.

The Company's trade receivables had two customers that represented more than 10% of the balance of trade receivables, representing 13.8% and 11.5% of the balance of trade receivables as at December 31, 2018 (2017 - two customers represented 16.0% and 14.8%). The Company believes that its expected credit losses are limited due to the protection afforded to the Company by the *Perishable Agricultural Commodities Act* (the "PACA") for its sales in the United States, which represent the majority of the Company's annual sales. The PACA protection gives a claim filed under the PACA first lien on all PACA assets (which include cash and trade receivables of the debtor).

As at December 31, 2018, the allowance for doubtful accounts balance was calculated based on the expected credit loss model and expected credit losses continues to be insignificant.

At December 31, 2018, 90.3% (2017 - 89.4%) of trade receivables were outstanding less than 30 days, 8.3% (2017 - 7.4%) were outstanding for between 30 and 90 days and the remaining 1.4% (2017 - 3.2%) were outstanding for more than 90 days. Trade receivables are considered past due based on the contract terms agreed to with a customer. Aged receivables that are past due are not considered impaired unless customer specific information indicates otherwise.

#### ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its long-term debt, for which the interest rates charged fluctuate based on the 90-day LIBOR rate. If interest rates had been 50 basis points higher, the net loss during the year ended December 31, 2018 would have been higher by \$182. This represents \$182 in increased interest expense (2017 - \$201).

#### iii) Foreign exchange risk

At December 31, 2018, the Canadian/U.S. foreign exchange rate was CA\$1.00 = US\$0.7336 (2017 – US\$0.7966). Assuming that all other variables remain constant, an increase of \$0.10 in the Canadian dollar would have the following impact on the ending balances of certain consolidated statements of financial position items at December 31, 2018 and December 31, 2017 with the net foreign exchange gain or loss directly impacting net income (loss) for the years.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

|  | December 31, 2018 |       | December 31, 2017 |       |
|--|-------------------|-------|-------------------|-------|
| Financial assets                       |                   |       |                   |       |
| Cash and cash equivalents              | \$                | 839   | \$                | 287   |
| Trade receivables                      |                   | 328   |                   | 349   |
| JV Note receivable                     |                   | 1,335 |                   |       |
| Financial liabilities                  |                   |       |                   |       |
| Trade payables and accrued liabilities |                   | (373) |                   | (371) |
| Loan payable                           |                   | (193) |                   | (232) |
| Net foreign exchange gain (loss)       | \$                | 1,936 | \$                | 33    |

#### iv) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The following are the contractual maturities of financial liabilities as at December 31, 2018:

| Financial liabilities          | Total        | -  | 1 year | 2  | -3 years | 4-5 | 5 years | e than<br>ears |
|--------------------------------|--------------|----|--------|----|----------|-----|---------|----------------|
| Long-term debt                 | \$<br>38,588 | \$ | 3,698  | \$ | 34,296   | \$  | 594     | \$<br>-        |
| Line of credit                 | 2,000        |    | 2,000  |    | -        |     | -       | -              |
| Trade payables                 | 14,601       |    | 14,601 |    | _        |     | -       | -              |
| Accrued liabilities            | 3,509        |    | 3,509  |    | -        |     | -       | _              |
| Obligation under capital lease | 180          |    | 78     |    | 92       |     | 10      | -              |
| Other liabilities              | 1,050        |    | -      |    | 1,050    |     | -       | -              |
| Total                          | \$<br>59,928 | \$ | 23,886 | \$ | 35,438   | \$  | 604     | \$<br>         |

It is the Company's intention to meet these obligations through the collection of current accounts receivable and cash from sales. If the current resources and cash generated from operations are insufficient to satisfy its obligations, the Company may seek to issue additional equity or to arrange debt or other financing. In addition, as at December 31, 2018, the Company has an operating credit facility of up to CA\$13,000, less outstanding letters of credit totaling US\$261 and CA\$38.

#### v) Fair values

The carrying amount of short-term financial instruments, less provisions for impairment if applicable, is consistent with the fair value of such instruments. The Company's debt bears a variable interest rate tied to market rates and therefore its carrying value approximates its fair value.

#### 13 RELATED PARTY TRANSACTIONS AND BALANCES

As at December 31, 2018, the Company had amounts due from its joint venture, Pure Sunfarms, totaling \$1,079 (December 31, 2017 - \$411) primarily for consulting services and the reimbursement of expenses which occurred in the year. These amounts were non-interest bearing and were due on demand. On July 5, 2018, the Shareholders entered into a Loan Agreement with Pure Sunfarms, whereby, as at December 31, 2018, the Shareholders had each contributed CA\$13,000 (US\$9,959) in the form of a demand loan to Pure Sunfarms. The loan amounts will initially bear simple interest at the rate of 8% per annum, calculated semi-annually. Interest will accrue and be payable upon demand being made by either Shareholder. These amounts are included in amounts due from joint venture in the consolidated statements of financial position.

One of the Company's employees is related to a member of the Company's executive management team and received \$108 in salary and benefits during the year ended December 31, 2018 (2017 - \$98).

Included in other assets as at December 31, 2018 is a \$64 (December 31, 2017 - \$70) promissory note that represents the unpaid amount the Company advanced to an employee in connection with a relocation at the request of the Company.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### 14 COMPENSATION OF KEY MANAGEMENT

Key management includes the Company's officers and vice presidents:

|                                      | Year Ended |             | Year Ended |              |  |
|--------------------------------------|------------|-------------|------------|--------------|--|
| December 31, 2018                    |            | er 31, 2018 | Decem      | ber 31, 2017 |  |
| Salaries and other employee benefits | \$         | 2,184       | \$         | 1,778        |  |
| Share-based payments                 |            | 629         |            | 1,104        |  |
|                                      | \$         | 2,813       | \$         | 2,882        |  |

#### 15 EXPENSES BY NATURE

The following table outlines the Company's significant expenses by nature:

| Cost of sales                                | Year Ended<br>December 31, 2018 |                                       | Year Ended<br>December 31, 2017 |              |  |
|--|---------------------------------|---------------------------------------|---------------------------------|--------------|--|
| Purchased produce                            | \$                              | 44,110                                | \$                              | 41,978       |  |
| Raw materials and consumables used           | 32,096                          |                                       | Ψ                               | 40,365       |  |
| Depreciation and amortization                |                                 | 6,911                                 |                                 | 7,447        |  |
| Transportation and storage                   |                                 | 21,074                                |                                 | 19,999       |  |
| Employee compensation and benefits           |                                 | 36,091                                |                                 | 34,644       |  |
| Employee compensation and benefits           | \$                              |                                       | \$                              |              |  |
|  | <u> </u>                        | 140,282                               | 3                               | 144,433      |  |
| Selling, general and administrative expenses | rative expenses Year Ended      |                                       | Ye                              | ar Ended     |  |
| December 31, 201                             |                                 | ber 31, 2018                          | December 31, 2017               |              |  |
| Employee benefits - salaries and short-term  |                                 | · · · · · · · · · · · · · · · · · · · |                                 |              |  |
| benefits                                     | \$                              | 8,360                                 | \$                              | 8,422        |  |
| Employee benefits - share-based payments     |                                 | 1,454                                 |                                 | 1,519        |  |
| Marketing                                    |                                 | 504                                   |                                 | 617          |  |
| Professional services                        |                                 | 2,120                                 |                                 | 1,705        |  |
| Office expenses                              |                                 | 1,680                                 |                                 | 1,671        |  |
| Other  |                                 | 1,444                                 |                                 | 1,479        |  |
|  | \$                              | 15,562                                | \$                              | 15,413       |  |
| Employees companyation and have site         | Va                              | ar Ended                              | Va                              | ar Ended     |  |
| Employee compensation and benefits           |                                 |                                       |                                 |              |  |
| 6.1  |                                 | ber 31, 2018                          |                                 | ber 31, 2017 |  |
| Salaries and short-term employee benefits    | \$                              | 44,451                                | \$                              | 43,066       |  |
| Share-based compensation                     | Φ.                              | 1,454                                 |                                 | 1,519        |  |
|  | \$                              | 45,905                                | \$                              | 44,585       |  |

#### 16 INCOME TAX EXPENSE

The provision for (recovery of) income taxes consists of the following components:

|  | ar Ended<br>ber 31, 2018 | Year Ended<br>December 31, 2017 |     |  |
|--|--------------------------|---------------------------------|-----|--|
| Current                                  | \$<br>431                | \$                              | 29  |  |
| Deferred                                 | (2,906)                  |                                 | 109 |  |
| Provision for (recovery of) income taxes | \$<br>(2,475)            | \$                              | 138 |  |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

The provision for (recovery of) income taxes reflected in the consolidated statements of (loss) income for the years ended December 31, 2018 and December 31, 2017 differs from the amounts computed at the federal statutory tax rates. The principal differences between the statutory income tax (recovery) and the effective provision for (recovery of) income taxes are summarized as follows:

|   | Year Ended |             | Year Ended        |       |  |
|---|------------|-------------|-------------------|-------|--|
|   | Decemb     | er 31, 2018 | December 31, 2017 |       |  |
| Income (loss) before income taxes               | \$         | (7,620)     | \$                | 3,960 |  |
| Tax (recovery) calculated at domestic tax       |            |             |                   |       |  |
| rates applicable in the respective countries    |            | (1,595)     |                   | 674   |  |
| Non-deductible items                            |            | 394         |                   | 422   |  |
| True up of prior year income tax estimates      |            | (206)       |                   | -     |  |
| Tax rate differences on deferred taxes          |            | -           |                   | (482) |  |
| State tax adjustments                           |            | -           |                   | (36)  |  |
| Foreign exchange on translation                 |            | -           |                   | 132   |  |
| Unrealized foreign exchange                     |            | (309)       |                   | 116   |  |
| Differences attributed to joint venture capital |            |             |                   |       |  |
| transactions                                    |            | (56)        |                   | (698) |  |
| Share of (income) losses from joint venture     |            | (611)       |                   | 66    |  |
| Other   |            | (92)        |                   | (56)  |  |
| Provision for (recovery of) income taxes        | \$         | (2,475)     | \$                | 138   |  |

The statutory tax rate in effect for the year ended December 31,2018 was 27.0% (2017 - 26.0%) in Canada and 21.0% (2017 - 23.0%) in the United States.

As a result of the US tax reform, the US federal tax rate was substantively enacted on December 22, 2017 and a reduced federal tax rate was effective from January 1, 2018 in accordance with the Tax Cuts and Jobs Act of 2017. Accordingly, the relevant deferred tax balances were re-measured with the new rate. As additional interpretations and regulatory guidance becomes available, the Company will continue to assess the impact of the new legislation.

The weighted average applicable tax rate was 32.3% tax benefit for 2018 (2017 - 3.5%).

#### 17 DEFERRED INCOME TAXES

Deferred tax assets

The deferred tax assets and liabilities presented on the consolidated statements of financial position are net amounts corresponding to their reporting jurisdiction. The deferred tax assets and liabilities presented in the note disclosure are grouped based on asset and liability classification without consideration of their corresponding reporting jurisdiction.

The amounts in the consolidated statements of financial position reconcile to the amounts disclosed in this note as follows:

| Deferred tax liabilities                                   | ,  |                              | (11,51   | (1,920) \$         |          | (12,431)<br>(4,825) |                |         |    |       |           |
|--|----|------------------------------|----------|--------------------|----------|---------------------|----------------|---------|----|-------|-----------|
| Deferred tax assets:                                       | (  | a losses/<br>other<br>redits |          | Γ Debt/<br>nterest | Inv      | ventory             | Inta           | ngibles | C  | ther  | Total     |
| At January 1, 2017   | \$ | 7,413                        | \$       | 3,190              | \$       | 518                 | \$             | 399     | \$ | 437   | \$ 11,957 |
| Charged to statement of income (loss) At December 31, 2017 |    | (2,289)<br>5,124             | <u> </u> | (968)<br>2,222     | <u> </u> | (144)<br>374        | <del></del> \$ | (399)   |    | (551) | (4,351)   |
| Credited (charged) to statement of (loss) income           | ф  | 1,053                        | ф.       | 524                |          | 133                 | \$             | -       | •  | 283   | 1,993     |
| At December 31, 2018                                       |    | 6,177                        |          | 2,746              | \$       | 507                 |                | -       | \$ | 169   | \$ 9,599  |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

| Deferred tax liabilities:   | <br>celerated<br>tax<br>preciation | logical<br>.sset | <br>valuation<br>Jurplus | Joint<br>Venture<br>Shares | Total          |
|---|------------------------------------|------------------|--------------------------|----------------------------|----------------|
| At January 1, 2017  | \$<br>(15,205)                     | \$<br>(674)      | \$<br>(1,065)            | \$<br>-                    | \$<br>(16,944) |
| Credited (charged) to<br>statement of income (loss)<br>Charged to statements of<br>other comprehensive (loss) | 6,179                              | 214              | -                        | (2,151)                    | 4,242          |
| income  | -                                  | -                | 271                      | -                          | 271            |
| At December 31, 2017  | \$<br>(9,026)                      | \$<br>(460)      | \$<br>(794)              | \$<br>(2,151)              | \$<br>(12,431) |
| Credited to statement of  |                                    |                  |                          |                            |                |
| (loss) income   | <br>567                            | <br>175          | <br>                     | 170                        | 912            |
| At December 31, 2018  | \$<br>(8,459)                      | \$<br>(285)      | \$<br>(794)              | \$<br>(1,981)              | \$<br>(11,519) |

The analysis of deferred tax assets and deferred tax liabilities is as follows:

|   | December   | 31, 2018 | December 31, 2017 |            |  |
|---|------------|----------|-------------------|------------|--|
| Deferred tax assets:                            | Canada     | U.S      | Canada            | U.S        |  |
| Expected to be recovered in more than 12 months | \$ 1,155   | \$ 7,465 | \$ 747            | \$ 5,753   |  |
| Expected to be recovered within 12 months       | 312        | 667      | 388               | 718        |  |
| Deferred tax liabilities:                       |            |          |                   |            |  |
| Expected to be settled in more than 12 months   | (4,181)    | (6,251)  | (4,606)           | (6,569)    |  |
| Expected to be settled within 12 months         | (41)       | (1,046)  | (40)              | (1,216)    |  |
| Deferred tax liabilities, net of assets         | \$ (2,755) | \$ 835   | \$ (3,511)        | \$ (1,314) |  |

Non-capital and farm losses expire as follows:

|      | Canada | U.S.      | Total     |
|------|--------|-----------|-----------|
| 2021 | \$ -   | \$ 8,402  | \$ 8,402  |
| 2022 | -      | 5,043     | 5,043     |
| 2023 | -      | 5,117     | 5,117     |
| 2024 | -      | 4,015     | 4,015     |
| 2025 | -      | 8,757     | 8,757     |
| 2027 | 25     | -         | 25        |
| 2028 | 4      | -         | 4         |
| 2029 | 25     | 64        | 89        |
| 2030 | 7      | -         | 7         |
| 2031 | 4      | 988       | 992       |
| 2032 | 4      | 14,895    | 14,899    |
| 2033 | 4      | -         | 4         |
| 2034 | 4      | 11,665    | 11,669    |
| 2035 | 108    | 7,445     | 7,553     |
| 2036 | 98     | 3,583     | 3,681     |
| 2037 | 98     | 5,570     | 5,668     |
| 2038 | 4      | 9,325     | 9,329     |
|      | \$ 385 | \$ 84,869 | \$ 85,254 |

Deferred income tax assets are recognized for tax loss carry-forwards to the extent that the realization of the related tax benefit through future profits is probable.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017 (In thousands of United States dollars, except per share amounts and unless otherwise noted)

#### 18 CHANGES IN NON-CASH WORKING CAPITAL ITEMS

|  | Fo | nber 31, |    |         |
|--|----|----------|----|---------|
|  |    | 2018     |    | 2017    |
| Trade receivables                            | \$ | (46)     | \$ | (1,059) |
| Inventories                                  |    | (5,180)  |    | (1,197) |
| Inventories reclassified to biological asset |    | (659)    |    | 306     |
| Other receivables                            |    | 172      |    | (1,396) |
| Income taxes payable                         |    | 68       |    | (246)   |
| Prepaid expenses and deposits                |    | 734      |    | 41      |
| Trade payables                               |    | 1,440    |    | 394     |
| Accrued liabilities                          |    | (121)    |    | (955)   |
| Other assets, net of other liabilities       |    | 42       |    | (305)   |
|  | \$ | (3,550)  | \$ | (4,417) |

#### 19 SEGMENT AND GEOGRAPHIC INFORMATION

The Company's two reporting segments include the Produce business and the Energy business. The Produce business produces, markets, and sells the product group which consists of premium quality tomatoes, bell peppers and cucumbers. The Energy business produces power that it sells per a long-term contract to its one customer.

The Company's primary operations are in the United States and Canada. Net sales by the countries in which its customers are located are as follows:

| For the Years Ended December 31 |         |                               |                            |  |
|---------------------------------|---------|-------------------------------|----------------------------|--|
| 2018                            |         | 2017                          |                            |  |
|                                 |         | ·                             |                            |  |
| \$                              | 124,699 | \$                            | 132,464                    |  |
|                                 | 23,355  |                               | 24,020                     |  |
|                                 | 1,946   |                               | 1,922                      |  |
| \$                              | 150,000 | \$                            | 158,406                    |  |
|                                 | \$      | \$ 124,699<br>23,355<br>1,946 | \$ 124,699 \$ 23,355 1,946 |  |

The Company's property, plant and equipment, net of accumulated depreciation, are located as follows:

|                 | Decem | December 31, 2018 |    | December 31, 2018 December 31 |  | ber 31, 2017 |
|-----------------|-------|-------------------|----|-------------------------------|--|--------------|
| United States   | \$    | 43,651            | \$ | 46,922                        |  |              |
| Canada          |       | 30,459            |    | 31,183                        |  |              |
| Energy - Canada |       | 3,369             |    | 3,649                         |  |              |
|                 | \$    | 77,479            | \$ | 81,754                        |  |              |

The depreciation and amortization charges for the year ended December 31, 2018 in the Produce business were \$6,154 (2017 - \$6,791) and \$873 (2017 - \$795) in the Energy business.

#### 20 SHARE CAPITAL AND EQUITY

The following is a summary of share capital:

|  | The VFF Com | The VFF Common Shares |  |  |  |
|--|-------------|-----------------------|--|--|--|
|  | # of Shares | Amount                |  |  |  |
| Share capital - January 1, 2017                  | 38,882,945  | \$ 24,954             |  |  |  |
| Shares issued pursuant to public offering, net   | 2,500,000   | 9,769                 |  |  |  |
| Shares issued from vesting of RSUs               | 768,000     | 1,333                 |  |  |  |
| Shares issued on exercise of options             | 91,667      | 59                    |  |  |  |
| Share capital - December 31, 2017                | 42,242,612  | 36,115                |  |  |  |
| Shares issued pursuant to public offering, net   | 3,097,200   | 15,737                |  |  |  |
| Shares issued pursuant to private placement, net | 1,886,793   | 7,755                 |  |  |  |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

| Shares issued from vesting of RSUs   | 50,334     | 831       |
|--------------------------------------|------------|-----------|
| Shares issued on exercise of options | 365,732    | 283       |
| Share capital - December 31, 2018    | 47,642,671 | \$ 60,721 |

VFF is authorized to issue an unlimited number of common shares and preferred shares, issuable in series. These shares have no par value.

#### (i) Common shares:

The common shares entitle the holders thereof to one vote per share at all shareholder meetings of VFF. The holders of the common shares are entitled to receive any dividend declared by VFF on the common shares. Subject to the rights, privileges, restrictions and conditions attached to any other class of shares of VFF, the holders of the common shares are entitled to receive, pro rata, the remaining property or assets of VFF upon its dissolution, liquidation or wind-up.

#### (ii) Preferred shares:

The preferred shares may be issued in one or more series, with such rights and conditions as may be determined by resolution of the directors of VFF who shall determine the designation, rights, privileges, conditions and restrictions to be attached to the preferred shares of such series. There are no voting rights attached to the preferred shares except as prescribed by law. In the event of the liquidation, dissolution or wind-up of VFF, or any other distribution of assets of VFF among its shareholders for the purpose of winding up its affairs, the holders of the preferred shares of each series are entitled to receive, among other things, with priority over the common shares and any other shares ranking junior to the preferred shares of VFF, an amount equal to any cumulative dividends, whether or not declared, or declared thereon but unpaid and no more. The preferred shares for each series are also entitled to such other preferences over the common shares and any other shares ranking junior to the preferred shares as may be determined as to their respective series authorized to be issued. The preferred shares of each series shall be on a parity basis with the preferred shares of every other series with respect to payment of dividends and return of capital. There are no preferred shares currently issued and outstanding.

#### 21 INCOME PER SHARE

Basic income per share is calculated by dividing the net income attributable to owners of the Company by the weighted average number of common shares in issue during the year excluding common shares purchased by the Company and held as treasury shares.

|  | For the Years Ended December 31, |         |      |        |  |
|--|----------------------------------|---------|------|--------|--|
|  |                                  | 2018    | 2017 |        |  |
| Net income (loss) attributable to owners of the Company          | \$                               | (5,145) | \$   | 3,822  |  |
| Weighted average number of common shares outstanding (thousands) |                                  | 44,357  |      | 39,144 |  |
| Basic income (loss) per share                                    | \$                               | (0.11)  | \$   | 0.10   |  |

Diluted income per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. The Company's share options are potentially dilutive to common shares. A calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares for the year) based on the monetary value of the subscription rights attached to outstanding share options. The number of shares calculated above is compared with the number of shares that would have been issued assuming the exercise of the share options. If dilutive effect is less than zero, then issuance is anti-dilutive and is excluded from dilutive income per share calculation.

For the year ended December 31, 2018, there were options to purchase 2,175 (2017 - nil) shares of the Company's common stock that were excluded from the diluted loss per share computation because the impact of the assumed exercise of such stock options would have been anti-dilutive during the respective periods.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

|  | For the Years Ended December 31, |         |    |        |  |
|--|----------------------------------|---------|----|--------|--|
|  | 2018                             |         |    | 2017   |  |
| Net income (loss) attributable to owners of the Company          | \$                               | (5,145) | \$ | 3,822  |  |
| Weighted average number of common shares outstanding (thousands) |                                  | 44,357  |    | 39,144 |  |
| Adjustment for:  |                                  |         |    |        |  |
| Share options (thousands)  |                                  | -       |    | 1,164  |  |
| Weighted average number of common shares outstanding for diluted |                                  |         |    |        |  |
| income per share (thousands)                                     |                                  | 44,357  |    | 40,308 |  |
| Diluted income (loss) per share                                  | \$                               | (0.11)  | \$ | 0.10   |  |

#### 22 CAPITAL DISCLOSURES

The Company's objectives when managing capital are to safeguard its assets and maintain a competitive cost structure, continue as a going concern and provide returns to its shareholders. In addition, the Company works with all relevant stakeholders to ensure the safety of its operations and employees and remain in compliance with all environmental regulations.

The Company's main objectives when managing capital are:

- to structure the repayment of obligations in line with the expected lives of the Company's principal revenue generating assets;
- to ensure the Company has access to capital to fund contractual obligations as they become due and to ensure adequate cash levels to withstand the impact of unfavorable economic conditions;
- to maintain the Company's credit ratings to facilitate access to capital markets at competitive interest rates; and
- to access capital markets to fund its growth initiatives.

The Company's capital comprises net debt and equity:

|                                | December 31, 2018 |          | December 31, 2017 |         |
|--------------------------------|-------------------|----------|-------------------|---------|
| Total bank debt                | \$                | 37,859   | \$                | 38,640  |
| Less cash and cash equivalents |                   | (11,920) |                   | (7,091) |
| Net debt                       |                   | 25,939   |                   | 31,549  |
| Total equity                   |                   | 100,696  |                   | 81,043  |
|                                | \$                | 126,635  | \$                | 112,592 |

It is the Company's intention to meet its obligations through the collection of current accounts receivable and cash. As at December 31, 2018, the Company has access to an operating loan facility up to CA\$13,000, less \$261 and CA\$38 outstanding letters of credit.

As at December 31, 2018, \$2,000 was outstanding on the operating loan (as at December 31, 2017, \$nil was outstanding on the operating loan, and \$261 and CA\$38 outstanding on the letters of credit). As at December 31, 2018, the operating loan borrowing base was CA\$11,509 based on a percentage of the Company's outstanding accounts receivable less the issued letters of credit. If the current resources and cash generated from operations are insufficient to satisfy its obligations, the Company may seek to issue additional equity or to arrange debt or other financing.

#### 23 SHARE-BASED COMPENSATION PLAN

The Company has a share-based compensation plan. The maximum number of common shares that can be issued upon the exercise of options granted is equal to 10% of the aggregate number of common shares issued and outstanding from time to time. The term during which an option may be exercised is 10 years from the date of the grant. Options vest at a rate of 33% per year, beginning one year following the grant date of the options. Share-based compensation expense for the year ended December 31, 2018 of \$1,454 (2017 - \$1,519) was recorded in selling, general and administrative expenses and the corresponding amount credited to contributed surplus.

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

The following table presents the assumptions used to establish the fair value assigned to the options issued using the Black-Scholes valuation model:

|                         | 2018      | 2017      |
|-------------------------|-----------|-----------|
| Expected volatility     | 55.5%     | 52.7%     |
| Dividend                | \$nil     | \$nil     |
| Risk-free interest rate | 2.70%     | 2.05%     |
| Expected life           | 6.5 years | 6.5 years |
| Fair value              | \$3.2541  | \$3.1869  |

The changes in the stock options for the years ended December 31, 2018 and 2017 were as follows:

|                   | For the Years Ended December 31, |                |               |                |  |
|-------------------|----------------------------------|----------------|---------------|----------------|--|
|                   | 2018                             |                | 2017          |                |  |
|                   | Weighted                         |                |               | Weighted       |  |
|                   |                                  | average        |               | average        |  |
|                   | Stock options                    | exercise price | Stock options | exercise price |  |
| Beginning of year | 2,337,732                        | CA\$1.59       | 2,116,065     | CA\$1.19       |  |
| Granted           | 203,000                          | CA\$5.79       | 320,000       | CA\$4.04       |  |
| Exercised         | (365,733)                        | CA\$0.98       | (91,667)      | CA\$0.90       |  |
| Forfeitures       | (10,000)                         | CA\$1.48       | (6,666)       | CA\$1.48       |  |
| End of year       | 2,164,999                        | CA\$2.10       | 2,337,732     | CA\$1.59       |  |

The following table summarizes stock options outstanding and granted as at December 31, 2018:

|                | Number      | Remaining contractual | Number of exercisable |
|----------------|-------------|-----------------------|-----------------------|
| Exercise price | outstanding | life (years)          | options               |
| CA\$1.24       | 425,000     | 2.4                   | 425,000               |
| CA\$1.27       | 150,000     | 3.2                   | 150,000               |
| CA\$0.85       | 100,000     | 4.2                   | 100,000               |
| CA\$1.10       | 202,000     | 4.7                   | 202,000               |
| CA\$1.48       | 345,000     | 5.2                   | 345,000               |
| CA\$0.94       | 100,000     | 6.2                   | 100,000               |
| CA\$0.83       | 20,000      | 6.8                   | 20,000                |
| CA\$0.80       | 16,666      | 6.9                   | 16,666                |
| CA\$1.43       | 233,333     | 7.3                   | 150,002               |
| CA\$1.55       | 50,000      | 7.5                   | 33,334                |
| CA\$2.20       | 165,000     | 8.5                   | 54,999                |
| CA\$6.00       | 155,000     | 9.0                   | 51,669                |
| CA\$5.79       | 203,000     | 9.6                   | Nil                   |
|                | 2,164,999   |                       |                       |

Share options outstanding at the end of the year have the following expiry dates and exercise prices:

|                                  | Exercise price in CA\$ per share | December 31,<br>2018 | December 31, 2017 |
|----------------------------------|----------------------------------|----------------------|-------------------|
| Expiry date - January 13, 2020   | 0.70                             |                      | 149,399           |
| Expiry date - May 20, 2021       | 1.24                             | 425,000              | 565,000           |
| Expiry date - March 13, 2022     | 1.27                             | 150,000              | 150,000           |
| Expiry date - March 13, 2023     | 0.85                             | 100,000              | 100,000           |
| Expiry date - September 26, 2023 | 1.10                             | 202,000              | 215,000           |
| Expiry date - March 18, 2024     | 1.48                             | 345,000              | 360,000           |
| Expiry date - March 19, 2025     | 0.94                             | 100,000              | 100,000           |
| Expiry date - October 6, 2025    | 0.83                             | 20,000               | 28,333            |

Notes to Consolidated Financial Statements for the Years Ended December 31, 2018 and 2017

(In thousands of United States dollars, except per share amounts and unless otherwise noted)

| Expiry date - November 16, 2025 | 0.80 | 16,666    | 50,000    |
|---------------------------------|------|-----------|-----------|
| Expiry date - March 29, 2026    | 1.43 | 233,333   | 250,000   |
| Expiry date - June 30, 2026     | 1.55 | 50,000    | 50,000    |
| Expiry date - June 14, 2027     | 2.20 | 165,000   | 165,000   |
| Expiry date - December 22, 2027 | 6.00 | 155,000   | 155,000   |
| Expiry date - June 5, 2028      | 5.79 | 203,000   | -         |
|                                 |      | 2,164,999 | 2,337,732 |

During 2018, 979,000 performance-based restricted share units were issued to Village Farms employees involved with future developments of the Company. Once a performance target is met and the share units are deemed earned and vested, compensation expense based on the fair value of the share units on the grant date is recorded in selling, general and administrative expenses in the consolidated statements of income. There were 1,056,666 performance-based restricted share units outstanding as at December 31, 2018, of which 881,333 were not vested as at December 31, 2018.

The following table summarizes 979,000 performance-based restricted share units that were issued during the year.

|                               | 2018             |                 | 2017             |                 |  |
|-------------------------------|------------------|-----------------|------------------|-----------------|--|
|                               | Performance-     | Weighted        | Performance-     | Weighted        |  |
|                               | based            | average grant   | based            | average grant   |  |
|                               | restricted share | date fair value | restricted share | date fair value |  |
|                               | units            | in CA\$         | units            | in CA\$         |  |
| Beginning of year             | 128,000          | CA\$2.82        | -                |                 |  |
| Issued                        | 979,000          | CA\$5.79        | 885,000          | CA\$2.20        |  |
| Issued                        | -                |                 | 21,000           | CA\$6.00        |  |
| Vested                        | (50,334)         | CA\$3.06        | (768,000)        | CA\$2.20        |  |
| Expired                       |                  |                 | (10,000)         | CA\$2.20        |  |
| Outstanding at end of year    | 1,056,666        | CA\$5.56        | 128,000          | CA\$2.82        |  |
| Earned but unissued at end of |                  |                 |                  |                 |  |
| year                          | 175,333          | CA\$5.08        |                  |                 |  |

#### 24 SUBSEQUENT EVENT

On February 15, 2019 the Company announced that its common shares were approved for listing on the Nasdaq Capital Market under the symbol "VFF". The initial trading date was February 21, 2019. Concurrent with the commencement of trading of its common shares on Nasdaq, the Company voluntarily delisted its common shares from the OTCQX.

On March 1, 2019 the Company announced that it had entered into an agreement with Nature Crisp LLC ("Nature Crisp") to form a joint venture for the outdoor cultivation of high-cannabidiol (CBD) hemp and CBD extraction in multiple states throughout the United States (the "Joint Venture Agreement"). The joint venture, Village Fields Hemp ("Village Fields"), will be 65% owned by Village Farms and 35% owned by Nature Crisp. Under the terms of the Joint Venture Agreement, Village Farms will contribute approximately US\$15 million to Village Fields for start-up costs and working capital.